Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6604709.pdf
Reference12 articles.
1. Carroll VA, Ashcroft M (2006) Role of hypoxia-inducible factor (HIF)-1alpha vs HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von hippel-lindau function: implications for targeting the HIF pathway. Cancer Res 12: 6264–6270
2. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 9: 734–745
3. Gillessen S, Graf L, Korte W, Cerny T (2007) Macrocytosis and cobalamin deficiency in patients treated with sunitinib. N Engl J Med 356 (22): 2330–2331
4. Hagerkvist R, Sandler S, Mokhtari D, Welsh N (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 21: 618–628
5. Hamberg P, de Jong FA, Boonstra JG, van Doorn J, Verweij J, Sleijfer S (2006) Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol 24 (18): e30–e31
Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Prevalence of diabetes and hospitalization due to poor glycemic control in people with bladder cancer or renal cell carcinoma in Sweden;BMC Urology;2024-07-17
2. Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review;Frontiers in Pharmacology;2024-02-01
3. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy;Genes;2024-01-28
4. Approach to the Patient: Insulinoma;The Journal of Clinical Endocrinology & Metabolism;2023-10-31
5. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management;Signal Transduction and Targeted Therapy;2023-07-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3